Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Howard R. Terebelo, DO
Providence Hospital
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Osteopathic Medical Oncology and Hematology, P.C.
Clinton Township, Michigan, United States
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
- Henry Ford Hospital
Detroit, Michigan, United States
- Garden City Hospital
Garden City, Michigan, United States
- Marquette General Hospital
Marquette, Michigan, United States
- Providence Hospital Cancer Center
Southfield, Michigan, United States
- Cleveland Clinic Cancer Center
Cleveland, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 1997
- Primary completion
- —
- Completion
- —
- Last update posted
- 6 Nov 2013
- Registered enrollment
- 36
- Registry id
- NCT00003123
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.